BAIRD 2025 GLOBAL INDUSTRIALS CONFERENCE UNION PACIFIC CORPORATION JIM VENA – CHIEF EXECUTIVE OFFICER JENNIFER HAMANN – CHIEF FINANCIAL OFFICER Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be 1 Cautionary Information 2 3 Strategic Execution Driving Industry Leading Results SAFETY + SERVICE & OPERATIONAL EXCELLENCE 210 219 215 221 226 238 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25** 86% 89% 94% 99% 98% 100% 89% 96% 93% 97% 100% 100% Q3'24 Q4 ...

Financial Performance & Growth - Q3 2025 total revenue reached $87.3 million, a 69% year-over-year increase[10] - Q3 2025 U S net product sales were $40.7 million, a 31% year-over-year increase[10] - Retail prescription equivalents increased by 9% quarter-over-quarter[11] Market Access & Awareness - Achieved 87% Medicare and 86% commercial approval rates for NEXLETOL and NEXLIZET, with average $29/$36 copays for a 30-day supply[16] - Launched a connected-TV ad campaign on Hulu and Disney+, expected to deliver approximately 18 million impressions targeting adults 50+ with prior statin use[16] Statin Intolerance & Bempedoic Acid - Up to 30% of U S adults experience some degree of statin intolerance[18] - Approximately 29% of patients discontinue their statin within the first year[31] - In the CLEAR Outcomes trial, bempedoic acid demonstrated a 13% relative risk reduction (RRR) in the primary composite endpoint (MACE-4) compared to placebo[48] - In primary prevention patients, bempedoic acid showed a 32% RRR in MACE-4 compared to placebo[52] Clinical Trial Data - CLEAR Outcomes trial showed a 27% RRR in nonfatal myocardial infarction with bempedoic acid compared to placebo[48] - CLEAR Outcomes trial showed a 19% RRR in coronary revascularization with bempedoic acid compared to placebo[48]

AMD Strategy and Vision - AMD aims to drive accelerated growth and deliver shareholder value[3] - The company expects leadership in high-performance and AI computing[3] - AMD anticipates growth and opportunities in the total addressable market[3] - AMD's goal is to deliver significant value to its shareholders[3] Financial Expectations - The presentation includes expectations of AMD's financial plans and long-term financial model, including compound annual growth rate, revenue market share, non-GAAP gross margin, non-GAAP operating margin, non-GAAP effective tax rate, non-GAAP FCF margin and non-GAAP earnings per share[3] - Projected 2025 non-GAAP gross profit and operating profit exclude $800 million inventory and related charges associated with U S export restrictions recognized in Q2'25[5] - AMD uses a projected non-GAAP tax rate of 13-15% for its long-term financial model[5] Meeting Agenda - The AMD Financial Analyst Meeting 2025 includes presentations on AMD's vision and growth strategy, technology strategy, data center leadership, AI leadership, networking, client, graphics, embedded transformation, and financial momentum[6]

THIRD QUARTER EARNINGS CALL NOVEMBER 11, 2025 OXY Cautionary statements Forward-Looking Statements This presentation contains "forward"-doking datements" withint temaning of the "safe factor" frouslisones of the Private Securities Libradition subt od initied to statemen (Ocodential ar Cav ) excectations, belefo; stars or for or of obsings statements in oly e estimates, expectains, probections, probections, robas and unertrianties. Actual seults, screetines materially: Forward-trading and dther strements reg ...

LEGEND Pivotal Cohort Protocol Amendment - The current LEGEND protocol includes changes such as performing a 2nd resection at the lesion site and restaging, which aligns with the standard of care and AUA Guidelines[8] - Enrollment is complete with 125 patients in the pivotal cohort, with 94 patients (75%) enrolled post-amendment and 31 patients (25%) pre-amendment[10, 11] Efficacy Data - Post-protocol amendment, the Intent-to-Treat (ITT) population (N=62) showed a Complete Response (CR) rate of 63% at any time, 56% at 3 months, and 62% at 6 months[14] - Pre-protocol amendment, the ITT population (N=31) showed a CR rate of 55% at any time, 55% at 3 months, and 41% at 6 months[18] - The 6-month CR rate for detalimogene post-amendment is 62%, which is trending competitively with novel products in the industry[25] Tolerability and Safety - In the entire Cohort 1 (n=125), 42.4% of patients experienced at least one Treatment-Related Adverse Event (TRAE), with zero discontinuations due to adverse events[30] - Detalimogene is trending towards best-in-class tolerability compared to other investigational agents and approved products, with a serious TRAE rate of 1.6%[31] Trial Progress and Enrollment - Enrollment rate was heavily skewed to the last 10 months, delaying insights into long-term efficacy[28, 35] - Additional cohorts are in progress, including BCG-Naïve, BCG-Exposed, and Papillary-Only NMIBC, with varying enrollment statuses[33]

Financial Performance - Free cash flow increased by 141% to $920 million in Q3 2025 compared to $381 million in Q3 2024[20] - Headline earnings increased by 185% to $672 million in Q3 2025 compared to $236 million in Q3 2024[20] - Adjusted EBITDA increased by 109% to $1.56 billion in Q3 2025 compared to $746 million in Q3 2024[20] - Basic earnings increased by 200% to $669 million in Q3 2025 compared to $223 million in Q3 2024[20] - The average gold price received increased by 40% to $3,490/oz in Q3 2025 from $2,486/oz in Q3 2024[80] Operational Performance - Gold production increased by 17% to 768,000 oz in Q3 2025 compared to 657,000 oz in Q3 2024[20] - Total cash costs for managed operations increased by 5% year-on-year to $1,244/oz in Q3 2025 from $1,186/oz in Q3 2024[20, 21] - All-in sustaining costs (AISC) for managed operations increased by 6% year-on-year to $1,766/oz in Q3 2025 from $1,665/oz in Q3 2024[79] Mineral Resources and Reserves - The Mineral Resource at the end of the financial year ended 31 December 2024 was estimated using a gold price of $1,900/oz[11] - The Mineral Reserve at the end of the financial year ended 31 December 2024 was estimated using a gold price of $1,600/oz[11]

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect, when made, our current views with respect to current events and financial performance. Such forward-looking statements are subject to many risks, uncertainties and factors relating to our operations and business environment, which may cause our actual results to be materially different from any future results, expressed or implied, by such forward-looking statements. ...

Investor Presentation November 2025 LGTMs: Date: Peter K. LGTM 11.10.25 Legal (Karen / Peter R.) LGTM Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.'s ("Clover Health," "we," "our," or "us") expectations regarding Adjusted EBITDA, Adjusted Net income from continuing operations, Adjusted SG&A, Adjusted SG&A as a percentage of revenue, Insurance BER, N ...

Financial Performance - Recurring EBITDA for Q3 2025 was US$150 million, a 104% increase compared to Q2 2025, but a 65% decrease compared to Q3 2024[8] - The company's cash position is approximately US$1.3 billion, providing about 27 months of coverage for debt maturities[9] - Liquidity stands at approximately US$2.3 billion, including cash and a stand-by credit line maturing in December 2026[9] Operational Highlights - The utilization rate in Brazil was 65%, a decrease of 9 percentage points compared to Q2 2025[9] - Green Ethylene utilization rate was 40%, a decrease of 31 percentage points compared to Q2 2025[9] - The utilization rate in the US & Europe was 79%, an increase of 5 percentage points compared to Q2 2025[9] - Mexico's utilization rate was 47%, an increase of 3 percentage points compared to Q2 2025[9] Market Scenario - The global macroeconomic environment remains volatile, impacting global demand and putting pressure on spreads in the international market[10] - There was soft demand in the third quarter across all regions, which is atypical for the season[11] - International market spreads have decreased to historically low levels due to an imbalance in global supply and demand[11] Strategic Initiatives - The company is implementing a Resilience and Transformation Program to address challenges in the petrochemical sector and enhance efficiency and competitiveness[74] - The company is advancing initiatives to increase gas-based capacity, optimize NAFTA-based operations, and transition to renewable resources[75]

Company Overview - Gentherm is a global market leader in innovative thermal management and pneumatic comfort technologies[5] - The company was founded in 1991 and is headquartered in Novi, MI[5] - Gentherm has over 14,000 employees and operates in 13 countries[5] Financial Performance (2024) - Revenue reached $1.5 billion[5] - Adjusted EBITDA was 12.6% of revenue[5] - Net leverage was 0.5x[5] - Automotive new business awards totaled $2.4 billion[5] Market Segmentation (2024 Revenue) - Automotive sector accounts for 67% of revenue[5] - Medical solutions contribute 3% of revenue[5] - Lumbar and massage comfort solutions represent 12% of revenue[5] - Valve systems make up 7% of revenue[5] - Other industries account for 11% of revenue[5] Strategic Growth Initiatives - The company is on track for $2 billion+ in Automotive New Business Awards this year[8] - Gentherm identified $300M+ lifetime revenue in target industries[8] Strategic Priorities - The company focuses on strategic priorities including channel and product expansion[8]